Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report Download FREE Resources

Published: April 24, 2024 Report Code: GDHC7120CTIDB-ST

Select Item

Hospital Acquired Pneumonia (HAP) Clinical Trial Report Overview

A total of 581 HAP clinical trials were conducted as of April 2024. The HAP clinical trial report provides a comprehensive understanding of the HAP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.

Key Regions ·       North America

·       Europe

·       Asia-Pacific

·       Middle East and Africa

·       South and Central America
Key Countries ·       United States

·       China

·       Iran

·       France

·       Spain
Key Sponsor Types ·       Company

·       Institution

·       Government
Leading Sponsors ·       Pfizer Inc

·       Merck & Co Inc

·       AstraZeneca Plc

·       F. Hoffmann-La Roche Ltd

·       Johnson & Johnson
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

HAP Clinical Trials Segmentation by Regions and Countries

As of April 2024, APAC led the HAP clinical trials landscape

The key regions considered for HAP clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

In the country-wise analysis, the US had the highest number of HAP clinical trials as of April 2024. Germany had the highest average patient enrollment in HAP clinical trials during the same time.

G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, France had the highest proportion of Hospital Acquired Pneumonia (HAP) to respiratory clinical trials as of April 2024.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil had the highest proportion of Hospital Acquired Pneumonia (HAP) to Respiratory clinical trials as of April 2024.

HAP Clinical Trials Analysis by Regions, 2024 (%)

HAP Clinical Trials Analysis by Regions, 2024 (%)

Buy the Full Report for More Regional Insights into the HAP Clinical Trials
Download a Free Sample Report

HAP Clinical Trials Segmentation by Sponsor Types

The key sponsor types for HAP clinical trials are company, institution, and the government. As of April 2024, the institution sponsor type conducted more than 52% of HAP clinical trials.

HAP Clinical Trials Analysis by Sponsor Types, 2024 (%)

HAP Clinical Trials Analysis by Sponsor Types, 2024 (%)

Buy the Full Report for More Sponsor Type Insights into the HAP Clinical Trials

Download a Free Sample Report

HAP Clinical Trials - Competitive Landscape

In 2024, Pfizer Inc conducted the highest number of HAP clinical trials

A few of the leading sponsors for HAP clinical trials are:

  • Pfizer Inc
  • Merck & Co Inc
  • AstraZeneca Plc
  • Hoffmann-La Roche Ltd
  • Johnson & Johnson

HAP Clinical Trials Analysis by Sponsors, 2024 (%)

HAP Clinical Trials Analysis by Sponsors, 2024 (%)

Buy the Full Report to Know More about the Leading Sponsors of HAP Clinical Trials

Download a Free Sample Report

Segments Covered in the Report

HAP Clinical Trials Regional Outlook (2024)

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South and Central America

HAP Clinical Trials Country Outlook (2024)

  • United States
  • China
  • Iran
  • France
  • Spain

HAP Clinical Trials Sponsor Type Outlook (2024)

  • Company
  • Institution
  • Government

Scope

  • The report provides a snapshot of the global clinical trials landscape.

  • The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.

  • The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.

  • The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.

  • The report provides enrollment trends for the past five years.

  • The report provides the latest news for the past three months.

Reasons to Buy

  • Formulate key business strategies with regard to investment.

  • Identify prominent locations for conducting clinical trials which saves time and cost.

  • Get top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.

  • Understand trial count and enrollment trends by country in the global therapeutics market.

  • Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.

  • Understand clinical trial assessment of the indication on a global, regional, and country level.

Pfizer Inc
Merck & Co Inc
AstraZeneca Plc
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Shionogi & Co Ltd
Wockhardt Ltd
Aridis Pharmaceuticals Inc
GSK plc
Qilu Pharmaceutical Co Ltd

Table of Contents

  • 1. Table of Contents

    • 1.1. List of Tables

    • 1.2. List of Figures

  • 2. Report Guidance

  • 3. GlobalData Clinical Trials Report Coverage

  • 4. Clinical Trials by Region

    • 4.1. Clinical Trials and Average Enrollment by Country

      • 4.1.1. Top Five Countries Contributing to Clinical Trials in Asia-Pacific

      • 4.1.2. Top Five Countries Contributing to Clinical Trials in Europe

      • 4.1.3. Top Countries Contributing to Clinical Trials in North America

      • 4.1.4. Top Five Countries Contributing to Clinical Trials in Middle East and Africa

      • 4.1.5. Top Five Countries Contributing to Clinical Trials in Central and South America

  • 5. Clinical Trials by G7 Countries: Proportion of HAP to Respiratory Clinical Trials

  • 6. Clinical Trials by Phase in G7 Countries

  • 7. Clinical Trials in G7 Countries by Trial Status

  • 8. Clinical Trials by E7 Countries: Proportion of HAP to Respiratory Clinical Trials

  • 9. Clinical Trials by Phase in E7 Countries

  • 10. Clinical Trials in E7 Countries by Trial Status

  • 11. Clinical Trials by Phase

    • 11.1. In Progress Trials by Phase

  • 12. Clinical Trials by Trial Status

  • 13. Clinical Trials by End Point Status

  • 14. Subjects Recruited Over a Period of Time

  • 15. Clinical Trials by Sponsor Type

  • 16. Prominent Sponsors

    • 16.1. Top Companies Participating in HAP Therapeutics Clinical Trials

  • 17. Prominent Drugs

  • 18. Clinical Trial Profile Snapshots

  • 19. Appendix

    • 19.1. Abbreviations

    • 19.2. Definitions

    • 19.3. Research Methodology

    • 19.4. Secondary Research

    • 19.5. About GlobalData

    • 19.6. Contact Us

    • 19.7. Source

Table

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region, 2024* 7_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 8_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 9_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024* 10_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries, 2024* 11_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries, 2024* 12_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024* 13_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024* 14_x000D_

Proportion of Hospital Acquired Pneumonia (HAP) to Respiratory Clinical Trials, G7 Countries (%), 2024* 15_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 16_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 18_x000D_

Proportion of Hospital Acquired Pneumonia (HAP) to Respiratory Clinical Trials, E7 Countries (%), 2024* 19_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 20_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 22_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase, 2024* 23_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase 2024* 24_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2024* 26_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2024* 27_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 28_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024* 29_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 31_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 32_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 33

Figures

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region (%), 2024* 7_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 8_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 9_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024* 10_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024* 11_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries (%), 2024* 12_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024* 13_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024* 14_x000D_

Proportion of Hospital Acquired Pneumonia (HAP) to Respiratory Clinical Trials, G7 Countries (%), 2024* 15_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 16_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 17_x000D_

Proportion of Hospital Acquired Pneumonia (HAP) to Respiratory Clinical Trials, E7 Countries (%), 2024* 19_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 20_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 21_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase (%), 2024* 23_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase, 2024* 24_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2024* 25_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2024* 27_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 28_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024* 29_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 30_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 32_x000D_

Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 33_x000D_

GlobalData Methodology 326

Frequently asked questions

Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Hospital Acquired Pneumonia (HAP) reports
Pharmaceuticals
New
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…
$3,495 | September 2026
Pharmaceuticals
New
Hodgkin Lymphoma: Epidemiology Report and Forecast
$9,995 | September 2026
Pharmaceuticals
New
Glioblastoma (GBM): Epidemiology Report and Forecast, 2026
$9,995 | September 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update in real time.

  • Access a live Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more